Case report: GLP1RA for the treatment of diabetes in liver transplanted people. Do they increase the risk of pancreatitis?

The incidence of acute pancreatitis (AP) in liver transplanted people is reported to be 1.5-8%. On the other hand, the evidence for a causal relationship between glucagon-like peptide 1 receptor agonists (GLP1RAs) and pancreatitis in people with type 2 diabetes is still weak. In addition, there are...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2024-05, Vol.15, p.1392371-1392371
Main Authors: Grancini, Valeria, Cogliati, Irene, Gaglio, Alessia, Resi, Veronica, Orsi, Emanuela
Format: Article
Language:English
Subjects:
acute pancreatitis
Diabetes Mellitus, Type 2 - complications
Endocrinology
Female
GLP1RAs
Glucagon-Like Peptide-1 Receptor - agonists
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
incretin agents
liver transplantation
Liver Transplantation - adverse effects
Male
Middle Aged
pancreatitis
Pancreatitis - etiology
Risk Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of acute pancreatitis (AP) in liver transplanted people is reported to be 1.5-8%. On the other hand, the evidence for a causal relationship between glucagon-like peptide 1 receptor agonists (GLP1RAs) and pancreatitis in people with type 2 diabetes is still weak. In addition, there are currently no data on a possible increased risk of AP in liver-transplanted individuals with diabetes treated with GLP1RAs. In a population of liver-transplanted individuals with diabetes receiving GLP1RA-based therapy, we reported an incidence of AP of 3.0% (two subjects). No cases were reported in liver-transplanted individuals with diabetes receiving SGLT2 inhibitors, insulin or metformin, neither in kidney or lung-transplanted patients treated with GLP1RAs. In both patients with AP, the only additional risk factor for its development was a history of re-transplantation (liver or combined kidney/liver). For this reason, we suggest particular caution when considering GLP1RAs-based therapies in liver transplanted patients with multiple risk factors for AP, such as a history of repeated and complex abdominal surgery.
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2024.1392371